Urine liver fatty acid binding protein and chronic kidney disease progression

References

• Kidney disease: improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1–150.
   Web of Science ®Google Scholar
• Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA. Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 2003;14:3217–32.
   PubMed Web of Science ®Google Scholar
• Kamijo A, Sugaya T, Hikawa A, Okada M, Okumura F, Yamanouchi M, Honda A, Okabe M, Fujino T, Hirata Y, Omata M, Kaneko R, Fujii H, Fukamizu A, Kimura K. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol 2004;165:1243–55.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Babazono T, Murata H, Iwamoto Y. Clinical significance of urinary liver-type fatty acid-binding protein in patients with diabetic nephropathy. Diabetes Care 2005;28:2038–9.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care 2005;28:2728–32.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Node K. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy. Am J Hypertens 2007;20:1195–201.
   PubMed Web of Science ®Google Scholar
• Panduru NM, Forsblom C, Saraheimo M, Thorn L, Bierhaus A, Humpert PM, Groop PH. Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 2013;36:2077–83.
   PubMed Web of Science ®Google Scholar
• Kamijo-Ikemori A, Sugaya T, Ichikawa D, Hoshino S, Matsui K, Yokoyama T, Yasuda T, Hirata K, Kimura K. Urinary liver type fatty acid binding protein in diabetic nephropathy. Clin Chim Acta 2013;424:104–8.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Sato E, Amaha M, Kawagoe Y, Maeda S, Yamagishi S. Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria. J Renin Angiotensin Aldosterone Syst 2012;13:122–7.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Fujiwara N, Kawagoe Y, Sugaya T, Ueda Y, Koide H. Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease. Eur J Clin Invest 2010;40:790–6.
   PubMed Web of Science ®Google Scholar
• Mou S, Wang Q, Li J, Shi B, Ni Z. Urinary excretion of liver-type fatty acid-binding protein as a marker of progressive kidney function deterioration in patients with chronic glomerulonephritis. Clin Chim Acta 2012;413:187–91.
   PubMed Web of Science ®Google Scholar
• Holzscheiter L, Beck C, Rutz S, Manuilova E, Domke I, Guder WG, Hofmann W. NGAL, L-FABP, and KIM-1 in comparison to established markers of renal dysfunction. Clin Chem Lab Med 2014;52:537–46.
   PubMed Web of Science ®Google Scholar
• Foster MC, Coresh J, Bonventre JV, Sabbisetti VS, Waikar SS, Mifflin TE, Nelson RG, Grams M, Feldman HI, Vasan RS, Kimmel PL, Hsu CY, Liu KD, Consortium CKDB. Urinary Biomarkers and Risk of ESRD in the Atherosclerosis Risk in Communities Study. Clin J Am Soc Nephrol 2015;10:1956–63.
   PubMed Web of Science ®Google Scholar
• Nielsen SE, Sugaya T, Hovind P, Baba T, Parving HH, Rossing P. Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care 2010;33:1320–4.
   PubMed Web of Science ®Google Scholar
• Nielsen SE, Andersen S, Zdunek D, Hess G, Parving HH, Rossing P. Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. Kidney Int 2011;79:1113–18.
   PubMed Web of Science ®Google Scholar
• Araki S, Haneda M, Koya D, Sugaya T, Isshiki K, Kume S, Kashiwagi A, Uzu T, Maegawa H. Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy. Diabetes Care 2013;36:1248–53.
   PubMed Web of Science ®Google Scholar
• Chou KM, Lee CC, Chen CH, Sun CY. Clinical value of NGAL, L-FABP and albuminuria in predicting GFR decline in type 2 diabetes mellitus patients. PLoS One 2013;8:e54863.
   PubMed Web of Science ®Google Scholar
• Minutolo R, Agarwal R, Borrelli S, Chiodini P, Bellizzi V, Nappi F, Cianciaruso B, Zamboli P, Conte G, Gabbai FB, De NL. Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease. Arch Intern Med 2011;171:1090–8.
   PubMed Web of Science ®Google Scholar
• Minutolo R, Gabbai FB, Agarwal R, Chiodini P, Borrelli S, Bellizzi V, Nappi F, Stanzione G, Conte G, De NL. Assessment of achieved clinic and ambulatory blood pressure recordings and outcomes during treatment in hypertensive patients with CKD: a multicenter prospective cohort study. Am J Kidney Dis 2014;64:744–52.
   PubMed Web of Science ®Google Scholar
• Khatir DS, Pedersen M, Ivarsen PR, Christensen KL, Jespersen B, Buus NH. Effects of intensified vasodilatory antihypertensive treatment on renal function, blood supply and oxygenation in chronic kidney disease. J Am Soc Nephrol 2015;26:241A.
   PubMed Web of Science ®Google Scholar
• Liu KD, Siew ED, Reeves WB, Himmelfarb J, Go AS, Hsu CY, Bennett MR, Devarajan P, Ikizler TA, Kaufman JS, Kimmel PL, Chinchilli VM, Parikh CR, Investigators A-AS. Storage Time and Urine Biomarker Levels in the ASSESS-AKI Study. PLoS One 2016;11:e0164832.
   PubMed Web of Science ®Google Scholar
• Kamijo A, Kimura K, Sugaya T, Yamanouchi M, Hikawa A, Hirano N, Hirata Y, Goto A, Omata M. Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med 2004;143:23–30.
   PubMed Web of Science ®Google Scholar
• Nielsen SE, Sugaya T, Tarnow L, Lajer M, Schjoedt KJ, Astrup AS, Baba T, Parving HH, Rossing P. Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care 2009;32:1684–8.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Nakayama M, Kanno M, Kimura H, Watanabe K, Tani Y, Hayashi Y, Asahi K, Terawaki H, Watanabe T. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial. Clin Exp Nephrol 2015;19:1044–53.
   PubMed Web of Science ®Google Scholar
• Matsui K, Kamijo-Ikemori A, Imai N, Sugaya T, Yasuda T, Tatsunami S, Toyama T, Shimizu M, Furuichi K, Wada T, Shibagaki Y, Kimura K. Clinical significance of urinary liver-type fatty acid-binding protein as a predictor of ESRD and CVD in patients with CKD. Clin Exp Nephrol 2016;20:195–203.
   PubMed Web of Science ®Google Scholar
• Hsu CY, Xie D, Waikar SS, Bonventre JV, Zhang X, Sabbisetti V, Mifflin TE, Coresh J, Diamantidis CJ, He J, Lora CM, Miller ER, Nelson RG, Ojo AO, Rahman M, Schelling JR, Wilson FP, Kimmel PL, Feldman HI, Vasan RS, Liu KD. Investigators CS, Consortium CKDB. Urine biomarkers of tubular injury do not improve on the clinical model predicting chronic kidney disease progression. Kidney Int 2017;91:196–203.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Fujiwara N, Sato E, Ueda Y, Sugaya T, Koide H. Renoprotective effects of various angiotensin II receptor blockers in patients with early-stage diabetic nephropathy. Kidney Blood Press Res 2010;33:213–20.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Inoue T, Fujiwara N, Kawagoe Y, Sugaya T, Ueda Y, Koide H, Node K. Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy. Clin Nephrol 2008;70:385–92.
   PubMed Web of Science ®Google Scholar
• Fufaa GD, Weil EJ, Nelson RG, Hanson RL, Bonventre JV, Sabbisetti V, Waikar SS, Mifflin TE, Zhang X, Xie D, Hsu CY, Feldman HI, Coresh J, Vasan RS, Kimmel PL, Liu KD. Chronic Kidney Disease Biomarkers Consortium I. Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus. Diabetologia 2015;58:188–98.
   PubMed Web of Science ®Google Scholar